- Conditions
- Eosinophilic Esophagitis, Milk Allergy
- Interventions
- Viaskin Milk 500 mcg, Viaskin Placebo
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Peanut Allergy
- Interventions
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 6 Years to 55 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 10
- States / cities
- San Diego, California • Stanford, California • Chicago, Illinois + 6 more
- Conditions
- Food Allergy
- Interventions
- Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • San Diego, California • Stanford, California + 9 more
- Conditions
- Peanut Allergy
- Interventions
- Whole peanut extract, Placebo formulation
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 6 Years to 50 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
- Conditions
- Allergy, Peanut Allergy
- Interventions
- DBV712 250 mcg, Placebo
- Combination Product
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 1 Year to 3 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
- Conditions
- Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
- Interventions
- Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Peanut Allergy
- Interventions
- Viaskin Peanut 250 mcg, Placebo
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more
- Conditions
- Peanut Allergy
- Interventions
- Viaskin Peanut 250mcg, Placebo
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
- Conditions
- Peanut Allergy
- Interventions
- Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 1 Year to 3 Years
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
- Conditions
- Peanut Allergy
- Interventions
- Dose A, Dose B, Dose C, Dose D, Dose E, Placebo
- Combination Product
- Lead sponsor
- Moonlight Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Atlanta, Georgia • Overland Park, Kansas + 2 more
- Conditions
- Allergy, Peanut
- Interventions
- DBV712, Placebo
- Drug · Other
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 4 Years to 7 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more